PfizerPFE
PFE logo
Fair Value
US$25.5
Share price04 Jan
US$24.822.7% undervalued intrinsic discount
Loading
1Y-2.13%
7D0%

Pfizer Inc. Delivers Resilient Q3 and 9M 2025 Performance with Strong EPS Outperformance, Cost Discipline and Strategic Repositioning

Open to work(+2349058909959-WhatsApp)Trading & Investment Signal:Field-Equity Research|Technical Analyst|Financial Market Securities(FX, Equities)Analyst|DEFI(cryptocurrency)Analyst|Investment banking|Primary Market|Portfolio Officer

Published
04 Jan 26
Views
288
Not Invested

Fair Value vs Share Price

US$25.5
vs US$24.822.7% undervalued intrinsic discount
PastFuture-288m93b20152018202120242026202720302031Revenue US$90.4bEarnings US$14.1b
7.6%
Revenue growth
15.6%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Pfizer

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Good value average dividend payer.

Market capUS$142.1b
PB1.6x
Estimated Growth-3.7%
Dividend Yield6.9%
Full analysis

CEO & management

Albert Bourla
CEO
6.2yrs
CEO Tenure

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.